{
    "eid": "2-s2.0-85107557582",
    "title": "The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials",
    "cover-date": "2022-03-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Nephrology",
            "@code": "2727",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Cardiovascular outcomes",
        "Chronic kidney disease",
        "Hyperphosphatemia",
        "Mortality",
        "Phosphate lowering agents"
    ],
    "authors": [
        "Jeerath Phannajit",
        "Natthaphon Wonghakaeo",
        "Kullaya Takkavatakarn",
        "Thanin Asawavichienjinda",
        "Kearkiat Praditpornsilpa",
        "Somchai Eiam-Ong",
        "Paweena Susantitaphong"
    ],
    "citedby-count": 4,
    "ref-count": 82,
    "ref-list": [
        "Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016",
        "Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention",
        "Phosphate\u2014the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review",
        "Mineral metabolism, mortality, and morbidity in maintenance hemodialysis",
        "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)",
        "Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials",
        "Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials",
        "Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis",
        "Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: a systematic review and NMA",
        "The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis",
        "Comparative efficacy and safety of phosphate binders in hyperphosphatemia patients with chronic kidney disease",
        "Effect of lanthanum carbonate on all-cause mortality in patients receiving maintenance hemodialysis: a meta-analysis of randomized controlled trials",
        "Phosphate binders for preventing and treating chronic kidney disease\u2010mineral and bone disorder (CKD\u2010MBD)",
        "Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients",
        "Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis-system review of lanthanum carbonate",
        "Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis\u2014a systematic review and meta-analysis of randomized controlled trials",
        "The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis",
        "Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis",
        "The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials",
        "A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States",
        "Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials",
        "Phosphate binders for preventing and treating bone disease in chronic kidney disease patients",
        "Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients",
        "A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients",
        "Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis",
        "Efficacy and safety of lanthanum carbonate on chronic kidney disease\u2014mineral and bone disorder in dialysis patients: a systematic review",
        "Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients",
        "Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients",
        "Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients",
        "Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism",
        "Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis",
        "Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis",
        "Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate",
        "Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients",
        "Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients",
        "The SLO-NIACIN Trial: a double-blind placebo controlled randomised cross-over trial of low dose slow-release niacin to lower phosphate in haemodialysis patients [ANZSN Abstract no.010]",
        "Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density",
        "Long-term comparison of a calcium-free phosphate binder and calcium carbonate\u2013phosphorus metabolism and cardiovascular calcification",
        "The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients",
        "Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years",
        "A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: A secondary analysis of the dialysis clinical outcomes revisited (DCOR) randomized trial using claims data",
        "Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients",
        "Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients",
        "Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients",
        "Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range",
        "Bias in meta-analysis detected by a simple, graphical test",
        "forestplot: advanced Forest Plot Using 'grid' Graphics",
        "R: A language and environment for statistical computing",
        "Effect of tenapanor on serum phosphate in patients receiving hemodialysis",
        "Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial",
        "Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis",
        "Sevelamer worsens metabolic acidosis in hemodialysis patients",
        "Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease",
        "Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis",
        "Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the COMBINE Trial",
        "Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study",
        "The phosphate binder equivalent dose",
        "Calcium balance in chronic kidney disease",
        "Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study",
        "Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial",
        "Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study",
        "Coronary artery calcification progression is associated with arterial stiffness and cardiac repolarization deterioration in hemodialysis patients",
        "Vascular calcification and QT interval in incident hemodialysis patients",
        "Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients",
        "Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease",
        "Fibroblast growth factor-23 and cardiovascular events in CKD",
        "Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community",
        "Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease",
        "Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis",
        "Mortality in kidney disease patients treated with phosphate binders: a randomized study",
        "Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study",
        "Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease",
        "The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer",
        "Cardiovascular effects of sevelamer in stage 3 CKD",
        "Effects of phosphate binders in moderate CKD",
        "Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial",
        "Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients",
        "Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?",
        "Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial",
        "Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis",
        "Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease",
        "A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD)"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60002620",
        "affilname": "Faculty of Medicine, Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Medical Library, Faculty of Medicine, Chulalongkorn University",
        "Chulalongkorn University"
    ]
}